
X
Alnylam soars after drug success, paving way for RNAi era
https://pharmaphorum.com/news/alnylam-shares-jump-rnai-drug-succeeds-rare-disease-trial/
Trials will resume once safety protocols have been reviewed.
Silence claims late-stage drugs infringe patents.
Biotech insists drug for rare inherited disorder is still approvable.
Biotech axes revusiran due to safety concerns.
UK base will be operational HQ, Switzerland to be official head office